Iowa Board of Pharmacy News, February 2012 by unknown
IA Vol. 25, No. 4 Page 1
Continued on page 4
400 SW 8th St, Suite E • Des Moines, IA  50309-4688 • Tel: 515/281-5944
Fax: 515/281-4609 • Web site: www.state.ia.us/ibpe
February 2012
Published to promote compliance of pharmacy and drug law
News
Iowa
Board of Pharmacy
Board Employees Retire  
Bernie Berntsen
Iowa Board of Pharmacy employee 
Bernie Berntsen, RPh, of Marion, IA, re-
tired on December 30, 2011. Bernie served 
as a compliance officer for seven years, 
beginning September 27, 2004. Prior to his 
tenure with the Board, Bernie worked as a 
community pharmacist for Walmart, Hy-
Vee, Pamida, and Econofoods at a variety 
of locations in eastern Iowa. (Pictured left: 
Bernie and his wife, Carol.)
Barb Lee
Board employee Barb Lee of 
Des Moines, IA, retired on Janu-
ary 3, 2012. She began her 33-year 
employment with the state of Iowa 
in October 1978 as an employee 
of the Department of Transporta-
tion. She came to the Board of 
Pharmacy as a clerk specialist on 
October 30, 1998, and served 13 
years in that position.
The Board thanks Bernie and Barb for their dedicated service to 
the Board and the public and wishes them a long and happy retire-
ment.
New Board Compliance Officer
Mark D. Mather
Mark D. Mather, RPh, of Robins, IA, began 
employment with the Board as a compliance of-
ficer on September 9, 2011. Mark is a graduate of 
the University of Iowa College of Pharmacy. He 
worked for Osco Drug/American Drug Stores 
in Marion, IA, from 1995 to 2000 and for Hy-
Vee in Cedar Rapids, IA,  from 2000 to 2011. 
Mark’s wife, Christine (Chris) Mather, is also 
a pharmacist. Mark’s current territory includes 
the following Iowa counties: Worth, Mitchell, 
Hancock, Cerro Gordo, Floyd, Humboldt, 
Wright, Franklin, Butler, Hamilton, Hardin, Grundy, Black Hawk, 
and Benton. Mark receives e-mail at Mark.Mather@iowa.gov. 
In Memory of  . . . 
Vennetta M. Fiedler
Former Board member Vennetta M. 
Fiedler of Spencer, IA, passed away on 
November 21, 2011, at the age of 97. Ven-
netta served as a public member of the 
Iowa Board of Pharmacy for nine years, 
from May 1, 1974 to April 30, 1983. Ven-
netta was born in Greenville, IA. She was a 
graduate of the Chicago School of Nursing. 
Vennetta was the first woman in Iowa to be 
licensed as a private investigator.   She also 
earned a private pilot’s license. Vennetta 
had an indomitable spirit. Her motto in life was “Just Do It.” She 
was active in the Red Cross, the Iowa Department of Elder Affairs, 
AARP, and a host of other groups. Vennetta never sat still. She was 
devoted to her family and the farm that she and her husband, Jack, 
had together. Vennetta’s record of involvement in local, state, and 
national organizations is a legacy of distinguished service and ac-
complishment. Her many contributions will long be remembered.
Iowa Prescription Monitoring Program  
Update
As of December 18, 2011, 2,956 prescribers and 1,208 pharmacists 
have registered to use the Iowa Prescription Monitoring Program. The 
number of data queries by prescribers grew by over 400% between 
2009 and 2011, from 16,806 queries in 2009 to 68,282 in 2011. The 
number of queries by pharmacists grew by nearly 40% during the 
same time period, from 5,703 queries in 2009 to 7,935 in 2011. The 
prescription monitoring program is showing significant increases in 
the use of controlled substances in Iowa. Since January 1, 2008, the 
number of patients receiving Schedule II medications increased from 
182,755 to 313,774 (a 71.7% increase). The number of total prescrip-
tions for  Schedule II, III, and IV controlled substances grew by 6.4% 
between 2008 and 2011. The program is successfully reducing the 
incidence of patients who utilize multiple pharmacies and multiple 
prescribers to obtain controlled substances. The number of patients 
who received controlled substances from five or more prescribers or 
pharmacies decreased by nearly 53% between 2009 and 2011, from 
3,293 incidents to 1,549. This downward trend is continuing in 2012. 
www.ismp.org. ISMP address: 200 Lakeside Dr, Suite 200, Horsham, 
PA 19044. Phone: 215/947-7797. E-mail: ismpinfo@ismp.org.
In the past few years, multiple studies have demonstrated that patients 
often leave medical encounters with a poor understanding of their health 
conditions and recommended treatment. One recent study on this subject 
demonstrates the low level of understanding patients have about follow-
up care and medication therapy upon discharge from the emergency 
department (Engel KG et al. Patient Comprehension of Emergency 
Department Care and Instructions: Are Patients Aware of When They Do 
Not Understand? Ann Emerg Med. Available on the journal Web site).
Given the importance of patient understanding of medical informa-
tion, there are surprisingly few studies that point out how to approach 
this task. However, a study published in 2008 offers some insight into 
what approach to assessing understanding of medical information pa-
tients most prefer and perceive to be the most effective (Kemp EC, et 
al. Patients Prefer the Method of “Tell Back-Collaborative Inquiry” to 
Assess Understanding of Medical Information. J Am Board Fam Med 
2008;21(1):24-30). Researchers tested three types of inquiry about the 
patient’s understanding:
 ♦ Yes-No
 ♦ Tell Back-Directive
 ♦ Tell Back-Collaborative
The Yes-No approach asked closed-ended questions to assess patient 
understanding. (Example: “I’ve given you a lot of information. Do you 
understand?”) The Tell Back-Directive method used open-ended ques-
tions that were physician-centered and paternalistic in that it was clear 
authority and control still remained with the physician. (Example: “It’s 
really important that you do this exactly the way I explained. What do 
you understand?”) The Tell Back-Collaborative approach used open-
ended questions that were patient centered, making it clear that power 
and responsibility were shared between the health care provider and 
patient. (Example: I imagine you are really worried about your blood 
pressure. I’ve given you a lot of information. It would be helpful to me 
to hear your understanding about your clot and its treatment.)
Patients showed a significant preference for the Tell Back-Collab-
orative inquiry over other tested approaches. Because of the potential 
for embarrassment if patient misunderstandings are exposed, one might 
anticipate health care providers’ reluctance to put patients “on the spot” 
with open-ended questions. But a collaborative approach to Tell Back 
allows the patient to save face for misunderstandings by acknowledg-
ing the large amount of information being provided. Patients might also 
view the request for Tell Back as evidence of the health care provider’s 
care and concern for them personally, or evidence of the provider’s at-
tention to detail and competence. So, when counseling patients about 
their medications, instead of asking “Do you have any questions?” or 
“Do you understand?” ask them to restate their understanding of the 
information you provided in their own words within a shame-free, 
blame-free environment.
DEA Clarifications on Certification Process for 
Audits of EPCS Software
Drug Enforcement Administration (DEA) emphasizes that third-party 
audits of software applications for Electronic Prescriptions for Controlled 
Substances (EPCS) must encompass all applicable requirements in 
DEA regulations, including security, and must address “processing 
integrity” as set forth in the regulations. Further, DEA recommends that 
where questions or gaps may arise in reviewing a particular applica-
Page 2
National Pharmacy Compliance News
(Applicability of the contents of articles in the National Pharmacy Compliance News to a particular state or jurisdiction should not be assumed 
and can only be ascertained by examining the law of such state or jurisdiction.)
FDA Recommends Use of Sterile Needle and 
Syringe for Administration of Inactivated 
Influenza Vaccines 
Food and Drug Administration (FDA) recommends that health care 
providers use a sterile needle and syringe to administer inactivated influ-
enza vaccines. The recommendation was released in response to ques-
tions regarding the use of jet injector devices to administer inactivated 
influenza vaccines. FDA advises that “inactivated influenza vaccines 
that are approved by FDA have information in their labeling stating how 
the vaccines should be administered, such as, by intramuscular (IM) or 
intradermal (ID) administration.” Further, FDA clarifies its October 21, 
2011 communication “to inform the public that inactivated influenza 
vaccines labeled for IM injection are intended for administration using 
a sterile needle and syringe. There is one inactivated influenza vaccine 
labeled for ID administration, this vaccine is supplied in its own pre-filled 
syringe. The live attenuated influenza vaccine is given through the nose 
as a spray; the sprayer is not a jet injector.” FDA also notes the following: 
 ♦ Currently, there is only one vaccine, Measles, Mumps, and Rubella 
(MMR), that is approved and specifically labeled for administration 
by jet injector. 
 ♦ Safety and effectiveness information that would support labeling 
inactivated influenza vaccines for delivery by jet injector have not 
been submitted to FDA.
 ♦ At this time, there are no inactivated influenza vaccines that are 
approved and specifically labeled by FDA for administration by jet 
injector.
FDA recommends that all approved vaccines, including influenza, be 
administered in accordance with their approved labeling, and FDA ad-
vises that if a vaccine has been approved for administration with a jet in-
jector, information specifically addressing vaccine use with a jet injector 
will appear in the vaccine labeling. Additional background information 
is available in the communication posted on the FDA Web site at www 
.fda.gov/BiologicsBloodVaccines/Vaccines/QuestionsaboutVaccines/
ucm276773.htm.
The Centers for Disease Control and Prevention continues to encour-
age people to get vaccinated throughout the flu season, which can begin 
as early as October and last as late as May. For information about the 
flu vaccine visit www.cdc.gov/flu.
‘Tell Back’ Works Best to Confirm Patient 
Understanding
This column was prepared by the Institute 
for Safe Medication Practices (ISMP). ISMP 
is an independent nonprofit agency that 
analyzes medication errors, near misses, and 
potentially hazardous conditions as reported 
by pharmacists and other practitioners. ISMP then makes appropriate 
contacts with companies and regulators, gathers expert opinion about 
prevention measures, and publishes its recommendations. To read about 
the risk reduction strategies that you can put into practice today, sub-
scribe to ISMP Medication Safety Alert!® Community/Ambulatory Care 
Edition by visiting www.ismp.org. ISMP is a federally certified patient 
safety organization, providing legal protection and confidentiality for 
submitted patient safety data and error reports. ISMP is also an FDA 
MedWatch partner. Call 1-800/FAIL-SAF(E) to report medication errors 
to the ISMP Medication Errors Reporting Program or report online at 
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tion, federal guidelines set forth in National Institute of Standards and 
Technology Special Publication 800 – 53A should be consulted. DEA 
has also announced the first DEA-approved certification process for 
EPCS. Certifying organizations with a certification process approved 
by DEA pursuant to the regulations are posted on DEA’s Web site at 
www.deadiversion.usdoj.gov/ecomm/e_rx/thirdparty.htm#approved. 
Detailed background information is provided in the Federal Register 
Notice, available for download at www.gpo.gov/fdsys/pkg/FR-2011-10-
19/pdf/2011-26738.pdf.
‘Script Your Future’ Provides Tools and Outreach 
to Encourage Medication Adherence
United States Surgeon General Regina Benjamin called upon 
pharmacists, physicians, nurses, and other health care providers to 
talk with their patients about the importance of taking medications 
as directed to help prevent serious health complications at the recent 
launch of the national campaign, “Script Your Future.” Benjamin also 
“encouraged patients with chronic conditions to speak with their health 
care professionals about their medication” as noted in a press release. 
A survey released by the National Consumer League, the organization 
that developed Script Your Future, indicates that “patients who do not 
always take their medication as directed are less likely to have received 
a full explanation of the consequences of their condition, and are less 
convinced of the importance of adherence.” The Script Your Future 
campaign is targeting six regional areas with outreach activities and 
advertising, and more information is available at www.ScriptYourFuture 
.org. The campaign brings together “stakeholders in health care, business, 
and government to offer practical tools for patients to help them better 
adhere to their medication, and to help health care professionals better 
communicate with patients.” More information about the campaign 
is available in a press release at www.prnewswire.com/news-releases/
us-surgeon-general-joins-baltimore-launch-of-the-national-script-
your-future-campaign-to-highlight-importance-of-taking-medication-
as-directed-133077423.html.
FDA Releases ‘Use Medicines Wisely’ Video 
FDA Office of Women’s Health has released a new public service 
announcement (PSA) video titled, “Use Medicines Wisely,” to help 
raise awareness about safe medication use. As stated in an FDA news 
release, “Millions of people benefit from FDA approved medications 
and are living longer productive lives. However, when medications are 
used incorrectly, they can cause serious injuries, even death. Many of 
these injuries can be prevented.”
The video shows simple steps women can take to use medications 
wisely. Viewers are reminded to: 
 ♦ Make a list of the medications they take
 ♦ Keep their medication list with them at all times
 ♦ Know the name of each medication, why they are taking it, how 
much to take, and when to take it 
 ♦ Talk with their doctor, nurse, or pharmacist to find out how to safely 
use their medications
In addition to the video, a medications record-keeper, fact sheets, and 
other safe medication use resources are available on the FDA Web site.
Training Video Provides Tips on Preventing 
Pharmacy Robbery 
Rx Pattern Analysis Tracking Robberies and Other Losses (RxPA-
TROL ) has released a training video discussing pharmacy robbery and 
how to prevent it. The video features a pharmacist and law enforcement 
liaison as they tour a pharmacy, evaluating security measures and discuss-
ing additional steps that can be taken to prevent robbery. RxPATROL 
is an initiative designed to collect, collate, analyze, and disseminate 
pharmacy theft intelligence to law enforcement throughout the nation. 
RxPATROL is designed to gather and disseminate critical information 
to help protect pharmacists, guard against potential robberies, and assist 
law enforcement in their efforts to successfully apprehend and prosecute 
those involved in controlled substance pharmacy crime. The training 
video can be accessed on the RxPATROL Web site at http://rxpatrol 
.org/TrainingVideos.aspx.
Nearly 20 Products Marketed as Natural 
Supplements Contain Sibutramine, FDA Warns 
FDA has posted public warnings regarding 19 products, frequently 
marketed as natural supplements, and found to contain sibutramine, a 
controlled substance that was removed from the US market in October 
2010 for safety reasons. These products pose a threat to consumers 
because sibutramine is known to substantially increase blood pressure 
and/or pulse rate in some patients and may present a significant risk for 
patients with a history of coronary artery disease, congestive heart failure, 
arrhythmias, or stroke. These products may also interact in life threaten-
ing ways with other medications a consumer may be taking. FDA warn-
ings included products marketed as “Slender Slim 11,” “Dream Body 
Slimming Capsule,” “Acai Berry Soft Gel ABC,” and 16 other product 
names. The products included in the warnings are being sold on Web 
sites and in some retail stores. FDA advises consumers not to purchase or 
use the products listed in the warnings. Consumers who have purchased 
any of these products should stop use immediately. And if consumers 
have experienced any negative side effects from using these products, 
they should consult a health care provider as soon as possible. The 
complete list of warnings is available on the FDA Web site at www.fda 
.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/
MedicationHealthFraud/ucm234592.htm.
2012 Survey of Pharmacy Law Now Available
Serving as a convenient reference source for individuals seeking 
an overview of the state laws and regulations that govern pharmacy 
practice, the updated 2012 Survey of Pharmacy Law is now available 
and can be purchased online for $195 by visiting the NABP Web site at 
www.nabp.net/publications.
The Survey, produced in a CD format, consists of four sections in-
cluding a state-by-state overview of organizational law, licensing law, 
drug law, and census data. Newly added this year, a question in Section 
17, Wholesale Distributor Licensure Requirements, asks which state 
agency has regulatory authority over medical device distributors. In 
addition, a newly added question in Section 22, Electronic Transmission 
of Prescriptions: Computer-to-Computer, asks whether the state allows 
electronic prescribing of controlled substances.
Updates for the 2012 Survey were graciously provided by the state 
boards of pharmacy. In addition to the boards’ support, NABP requested 
data from relevant health care associations for the Survey’s prescribing 
authority and dispensing authority laws in Sections 24 and 25, and laws 
pertaining to the possession of non-controlled legend drugs and posses-
sion of controlled substances in Sections 26 and 27. 
All final-year pharmacy students receive the Survey free of charge 
through the generous grant of Purdue Pharma L.P. 
For more information on the Survey, please contact Customer Service 
via phone at 847/391-4406 or via e-mail at custserv@nabp.net.
National Association of Boards of Pharmacy Foundation, Inc
1600 Feehanville Drive
Mount Prospect, IL 60056
IOWA BOARD OF PHARMACY
Presorted Standard
U.S. Postage
PAID
Chicago, Illinois
Permit No. 5744
Continued from page 1
Page 4 – February 2012
The Iowa Board of Pharmacy News is published by the Iowa Board of 
Pharmacy and the National Association of Boards of Pharmacy Foundation, 
Inc, to promote compliance of pharmacy and drug law. The opinions and 
views expressed in this publication do not necessarily reflect the official 
views, opinions, or policies of the Foundation or the Board unless expressly 
so stated.
Lloyd K. Jessen, JD, RPh - State News Editor
Carmen A. Catizone, MS, RPh, DPh - National News Editor  
& Executive Editor
Larissa Doucette - Communications Manager
Top 10 Controlled Substances in Iowa by Number 
of Doses Dispensed: January 1, 2011 to December 
18, 2011
Controlled 
Substance
No. of 
Prescriptions
Doses 
Dispensed
Approx.
Doses/
Prescription
Hydrocodone 1,209,256 72,277,615 60
Alprazolam 420,732 26,185,742 60
Oxycodone 304,138 23,852,290 80
Lorazepam 283,492 15,158,234 50
Clonazepam 257,211 15,102,650 60
Methylphenidate 303,452 14,275,858 50
Zolpidem 393,138 11,657,284 30
Amphetamine 231,708 11,292,611 50
Codeine 127,126 7,079,996 60
Morphine 80,570 5,663,264 70
Fifty-Year Pharmacists
The Board congratulates the following 19 Iowa pharmacists who 
were originally licensed in 1962, have  continuously maintained their 
Iowa pharmacist license, and have devoted a half-century of service 
to the public and the profession:
Larry D. Albrecht .....................................................Ida Grove, IA
Harry L. Bebensee .......................................................Gilbert, AZ
Robert G. Dean .......................................................Sioux City, IA
Arthur W. Fairfield ..................................................Sioux City, IA
Kenneth A. Fann ......................................................... Atlantic, IA
Robert C. Graef ........................................................Coralville, IA
Robert L. Griffiths .......................................................Okoboji, IA
Vernon L. Henrich ...........................................Missouri Valley, IA
Harry B. Jones III .......................................................Dunedin, FL
Richard L. Jensen ..................................................Des Moines, IA
Harold C. Jackson .....................................................Winterset, IA
Paul Q. Klufa ...................................................................Ames, IA
Carl W. Kolpin .................................................. Moose Lake, MN
Richard J. Miller .............................................. Council Bluffs, IA
Philip L. Metcalf ..............................................................Leon, IA
Terry K. Sampson ....................................................... Tucson, AZ
Marvin R. Smith .................................................... Mason City, IA
Marlin J. Stirm .............................................................Ankeny, IA
Robert L. Vaughn .................................................... Urbandale, IA
Board Meeting Calendar for 2012
The following meeting dates have been set for future Board 
meetings:
 ♦ March 6-7, 2012 (new date!)
 ♦ May 2-3, 2012
 ♦ June 26-27, 2012
 ♦ August 28-29, 2012
 ♦ November 7-8, 2012
These meetings will be held at the Board office in Des Moines. 
Meeting agendas will be posted on the Board’s Web site. Dates are 
subject to change. Please check with the Board office at 515/281-5944 
to confirm. 
Board Web Site
Please visit the Board’s Web site at www.state.ia.us/ibpe/. 
Board Mission
The Iowa Board of Pharmacy promotes, preserves, and protects 
the public health, safety, and welfare through the effective regula-
tion of the practice of pharmacy and the licensing of pharmacies, 
pharmacists, and others engaged in the sale, delivery, or distribution 
of prescription drugs and devices. Iowa Code §155A.2(1).
